A modern experimental medication, retatrutide, is showing remarkable promise in the treatment of type 2 diabetes and obesity, according to data released by its developer, Eli Lilly. In a 40-week clinical trial, participants experienced significant reductions in blood sugar levels and substantial weight loss – averaging nearly 40 pounds – raising hopes for a more effective approach to managing these often-overlapping conditions. The findings, while not yet published in a peer-reviewed medical journal, represent a potentially significant advancement in metabolic disease treatment.
The impact of type 2 diabetes and obesity extends far beyond individual health, placing a substantial burden on healthcare systems and contributing to a range of related complications. Current treatments often require a multi-faceted approach, including lifestyle modifications and medication, but many patients struggle to achieve and maintain optimal control. Retatrutide’s potential to address both blood sugar and weight simultaneously could offer a much-needed improvement in patient outcomes.
Retatrutide distinguishes itself from existing medications like Ozempic and Mounjaro by targeting three key metabolic hormones – GLP-1, GIP, and glucagon – earning it the moniker “triple G” drug. This broader action is believed to contribute to its enhanced efficacy. Gitanjali Srivastava, MD, medical director of Vanderbilt Obesity Medicine in Nashville, Tennessee, who was not involved in the study, described the results as “unprecedented.”
How Retatrutide Works: A Triple-Hormone Approach
Existing medications often focus on one or two of these hormones. Semaglutide (Ozempic) primarily targets GLP-1, while tirzepatide (Mounjaro) acts on both GLP-1 and GIP. Retatrutide’s inclusion of glucagon receptor activity appears to be a key differentiator. Christine Bonarrigo, PharmD, a weight management pharmacist at Tufts Medical Center in Boston, explains that GLP-1 and GIP work by reducing appetite and improving insulin secretion. “What differentiates retatrutide is the addition of glucagon receptor activity, which appears to increase energy expenditure and fat oxidation. So instead of just helping patients eat less, this therapy may as well support them burn more calories, essentially targeting both sides of the energy balance equation,” she said.
Clinical Trial Results: Significant Improvements in A1C and Weight
The phase 3 clinical trial, known as TRANSCEND-T2D-1, involved over 500 adults with type 2 diabetes whose blood sugar was not adequately controlled through diet and exercise alone. Participants had been living with diabetes for approximately 2.5 years and had not used diabetes medications for at least 90 days prior to the study. Participants were randomly assigned to receive either 4mg, 9mg, or 12mg of retatrutide, or a placebo, via weekly injection, with those in the higher-dose groups gradually increasing to their assigned dosage.
The results demonstrated a significant impact on both glycemic control and weight management. Participants receiving retatrutide experienced an A1C reduction of up to 2 percent, a measure of average blood sugar levels over two to three months. According to the American Diabetes Association, even a 1 percent reduction in A1C can significantly lower the risk of diabetes-related complications. Participants lost an average of 36.6 pounds, representing 16.8 percent of their initial body weight, with continued weight loss observed throughout the 40-week study period.
Comparing Retatrutide to Existing Medications
While the current trial did not directly compare retatrutide to semaglutide or tirzepatide, existing research offers some context. A 2023 study found that individuals with type 2 diabetes taking tirzepatide experienced a 1.3 percent reduction in A1C and lost an average of 22 pounds over a year, while those taking semaglutide saw a 0.9 percent A1C reduction and a 17-pound weight loss. The New England Journal of Medicine published the results of this study. Retatrutide’s trial showed A1C reductions up to 2 percent in less than a year, exceeding the results seen with both semaglutide and tirzepatide. Though, Christoph Buettner, MD, PhD, chief of the division of endocrinology at Rutgers Robert Wood Johnson Medical School in New Brunswick, New Jersey, cautioned that the difference wasn’t dramatically larger than that seen with tirzepatide, stating, “One might have expected a more pronounced improvement in glycemic control, given the degree of weight reduction.”
Side Effects and Ongoing Research
The most common side effects reported in the retatrutide trial were nausea (affecting 16 to 27 percent of participants, depending on dosage, compared to 3.7 percent on placebo), diarrhea (19 to 23 percent versus 5 percent), vomiting (16 to 18 percent versus 2 percent), and nerve issues (2 to 4 percent versus none). Between 2 and 5 percent of participants discontinued treatment due to side effects, with the highest rate observed in the 12mg dosage group. No participants in the placebo group stopped treatment early.
Eli Lilly is continuing to investigate retatrutide in several ongoing phase 3 clinical trials. These trials are evaluating its potential benefits for conditions frequently associated with obesity, including knee osteoarthritis, obstructive sleep apnea, chronic low back pain, and cardiovascular and renal health. The company is also studying its impact on liver disease.
Mir Ali, MD, medical director of MemorialCare Surgical Weight Loss Center in Fountain Valley, California, believes retatrutide could be a significant addition to the treatment landscape. “This could provide another significant treatment option for patients living with diabetes or obesity,” he said. Dr. Srivastava echoed this sentiment, adding, “Retatrutide could redefine standards for both diabetes and obesity care, offering patients deeper, more comprehensive metabolic improvements than previously possible.”
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The U.S. Food and Drug Administration (FDA) has not yet approved retatrutide for public leverage. Eli Lilly anticipates submitting data from these trials to the FDA for review in the coming months. The next key milestone will be the FDA’s decision on whether to approve the drug, which is expected sometime in 2026.
Have thoughts on this new research? Share your comments below, and share this article with anyone who might find it helpful.
